Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Infectious disease-focused Idenix Pharmaceuticals Inc. has netted $165.9mm through the follow-on public offering of 22mm common shares at $8.00 each. The company will use a portion of the proceeds for ongoing development activities, including combination Phase IIb trials of IDX184 with IDX719 for hepatitis C, and proof-of-concept and Phase IIa studies of IDX19368 in combination with ribavirin, also for HCV.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?